NuCana (NASDAQ:NCNA) Shares to Reverse Split on Tuesday, April 16th

Shares of NuCana plc (NASDAQ:NCNA) are set to reverse split on the morning of Tuesday, April 16th. The 1-25 reverse split was announced on Tuesday, April 16th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 16th.

NuCana Stock Performance

Shares of NuCana stock opened at $0.24 on Friday. The firm’s 50-day simple moving average is $0.31 and its 200-day simple moving average is $0.38. NuCana has a twelve month low of $0.22 and a twelve month high of $0.96. The firm has a market cap of $12.37 million, a P/E ratio of -0.37 and a beta of 0.92.

NuCana (NASDAQ:NCNA) last issued its earnings results on Wednesday, March 20th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). On average, equities analysts forecast that NuCana will post -0.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Oppenheimer restated an “outperform” rating and issued a $4.00 price target on shares of NuCana in a research report on Monday, April 1st.

Hedge Funds Weigh In On NuCana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NCNA. Acadian Asset Management LLC boosted its position in NuCana by 163.2% in the first quarter. Acadian Asset Management LLC now owns 522,532 shares of the company’s stock valued at $520,000 after buying an additional 324,010 shares in the last quarter. Virtu Financial LLC lifted its position in shares of NuCana by 167.8% during the first quarter. Virtu Financial LLC now owns 77,952 shares of the company’s stock worth $78,000 after purchasing an additional 48,845 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of NuCana by 10.4% during the second quarter. Renaissance Technologies LLC now owns 371,433 shares of the company’s stock worth $269,000 after purchasing an additional 35,100 shares in the last quarter. Citadel Advisors LLC lifted its position in shares of NuCana by 88.6% during the third quarter. Citadel Advisors LLC now owns 63,531 shares of the company’s stock worth $66,000 after purchasing an additional 29,852 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in shares of NuCana by 208.3% during the first quarter. Commonwealth Equity Services LLC now owns 66,600 shares of the company’s stock worth $63,000 after purchasing an additional 45,000 shares in the last quarter. 44.00% of the stock is currently owned by institutional investors and hedge funds.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.